Richard Henriques Net Worth

The estimated Net Worth of Richard C Jr Henriques is at least $199 Thousand dollars as of 24 August 2015. Mr. Henriques owns over 1,000 units of Cabaletta Bio Inc stock worth over $4,260 and over the last 9 years he sold CABA stock worth over $0. In addition, he makes $194,827 as Independent Director at Cabaletta Bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Henriques CABA stock SEC Form 4 insiders trading

Richard has made over 1 trades of the Cabaletta Bio Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of CABA stock worth $6,950 on 24 August 2015.

The largest trade he's ever made was buying 1,000 units of Cabaletta Bio Inc stock on 24 August 2015 worth over $6,950. On average, Richard trades about 63 units every 0 days since 2015. As of 24 August 2015 he still owns at least 1,000 units of Cabaletta Bio Inc stock.

You can see the complete history of Mr. Henriques stock trades at the bottom of the page.

Richard Henriques biography

Richard Conover Henriques Jr. serves as Independent Director of the Company. He joined Cabaletta’s Board of Directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr. Henriques was the chief financial officer of the Bill & Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program related investments and information technology. From 1981 to 2008, Mr. Henriques held positions at Merck & Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr. Henriques also serves on the boards of directors of EMulate Therapeutics Inc. (formerly Nativis Inc.), Arbutus Biopharma Corporation, the Pennsylvania chapter of the Nature Conservancy and Episcopal Community Services, and on the board of trustees of the Franklin Institute.

What is the salary of Richard Henriques?

As the Independent Director of Cabaletta Bio Inc, the total compensation of Richard Henriques at Cabaletta Bio Inc is $194,827. There are 7 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of $1,528,630.

How old is Richard Henriques?

Richard Henriques is 64, he's been the Independent Director of Cabaletta Bio Inc since 2019. There are no older and 14 younger executives at Cabaletta Bio Inc.

What's Richard Henriques's mailing address?

Richard's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.

Insiders trading at Cabaletta Bio Inc

Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport..., and James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.

What does Cabaletta Bio Inc do?

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un

Complete history of Mr. Henriques stock trades at Arbutus Biopharma Corp and Cabaletta Bio Inc

Cabaletta Bio Inc executives and stock owners

Cabaletta Bio Inc executives and other stock owners filed with the SEC include:

• Anup Marda,
  Chief Financial Officer
• Steven Nichtberger,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Gwendolyn Binder-Scholl,
  Executive Vice President, Science & Technology
• Dr. Steven A. Nichtberger M.D.,
  Co-Founder, Chairman, CEO & Pres
• Dr. Steven A. Nichtberger,
  Co-Founder, Chairman, CEO & Pres
• Dr. David J. Chang M.D., M.P.H.,
  Chief Medical Officer
• Dr. Gwendolyn K. Binder,
  Exec. VP of Science & Technology
• Richard Henriques,
  Independent Director
• Catherine Bollard,
  Independent Director
• Mark Simon,
  Independent Director
• Brian Daniels,
  Independent Director
• David Chang,
  Chief Medical Officer
• J. Brian Stalter,
  General Counsel
• Michael Gerard J.D.,
  Gen. Counsel & Sec.
• Heather Harte-Hall M.Sc.,
  Chief Compliance Officer
• Michael Gerard,
  Gen. Counsel
• Dr. Samik Basu M.D.,
  Chief Scientific Officer
• Martha O'Connor,
  Chief HR Officer
• J. Brian Stalter J.D.,
  Gen. Counsel
• Dr. Aimee Payne M.D., Ph.D.,
  Co-Founder & Co-Chair of Scientific Advisory Board
• Dr. Michael C. Milone M.D., Ph.D.,
  Co-Founder & Co-Chair of Scientific Advisory Board
• Anup Marda M.B.A.,
  Chief Financial Officer
• Shawn Tomasello,
  
• Scott C. Brun,
  
• Gwendolyn Binder,
  See Remarks
• Arun Das,
  Chief Business Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Ventures V, L.P.5 Am Opport...,
  
• Michael Gerard,
  General Counsel